Intervacc's Strangles Vaccine Hits Near-Perfect Protection at 100,000 Doses — But Can a Six-Cent Stock Convert Proof Into Profit?

Shares of Intervacc AB surged +12% on November 3 after the Swedish animal-vaccine maker reported that its horse strangles vaccine delivered near-100% real-world protection across 100,000 doses sold in the EU and UK, with only three confirmed infections among fully vaccinated horses. The data point is striking — but the company behind it remains deeply unprofitable, raising the question of whether clinical validation alone can close a yawning financial gap.

• Real-World Data Is the Best Marketing a Niche Vaccine Can Get. Clinical trials prove a vaccine can work; field data proves it does work. For veterinarians deciding whether to add a new shot to their protocols, a near-perfect track record across 100,000 doses is a powerful sales tool. Strangvac sales in Sweden jumped 148% in Q1 2026 versus the prior year , and rolling twelve-month dose sales across Sweden and the EU rose 58% . Today's data should accelerate that adoption curve in markets where the vaccine recently launched — now spanning 15 countries including France, Germany, the UK, and Spain .

• The Revenue Base Is Still Tiny Relative to the Losses. Intervacc's trailing twelve-month revenue sits at roughly SEK 18 million against losses of SEK 92 million . H1 2026 net sales came in at just SEK 9.6 million , and while Swedish revenue grew 54%, European revenue outside Scandinavia actually fell 63% . At a market cap around SEK 350 million, investors are pricing in future growth — not today's cash flows. Cash stood at SEK 128 million at mid-year, down SEK 33 million in six months , giving the company roughly two years of runway at the current burn rate.

• The U.S. Is the Make-or-Break Market. The U.S. has approximately 10 million horses — dwarfing Europe's installed base. Safety trials involving ~600 horses across four states began in late 2025, with efficacy studies planned for the second half of 2026 . U.S. approval would transform Intervacc's addressable market overnight, but the timeline remains uncertain.

• A Booster-Friendly Label Could Change the Math. Intervacc submitted a regulatory application to the EMA seeking a 12-month duration of immunity for its vaccine . If approved, it would simplify booster schedules and potentially double recurring revenue per horse per year — a critical lever for a company that needs volume to reach breakeven.

The vaccine works. The remaining question — and the one this stock price ultimately answers — is whether Intervacc can turn clinical proof into commercial scale before the cash runs out.